©2024 Stanford Medicine
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
Not Recruiting
Trial ID: NCT04697056
Purpose
Efficacy and Safety of imsidolimab in Participants with Ichthyosis
Official Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Subjects With Ichthyosis
Stanford Investigator(s)
Joyce Teng, MD, PhD
Professor of Dermatology and, by courtesy, of Pediatrics
Eligibility
Inclusion Criteria:
- Diagnosis of Ichthyosis
- IASI total score ≥ 18, erythema score ≥ 2
- Participant has been using emollient daily for at least 1 week prior to Day 1 and
agrees to continue using that same emollient daily at the same frequency throughout
the study
Exclusion Criteria:
- A participant with ichthyosis vulgaris, X-linked ichthyosis, or lamellar ichthyosis
will be excluded.
Intervention(s):
biological: placebo
drug: Imsidolimab
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
SPECTRUM
650-723-0363